AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27096858
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with fasting prescription 6-8 hours before surgery
Trial: 24450319
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose frequency (HDF) - five 1‐hr sessions per week
Trial: 24450319
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose frequency (LDF) - one 1‐hr session per week
Trial: 23427390
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese spinal orthopedic manipulation (TCSOM), 5 treatments
Trial: 16899479
Drug: Topical beclometasone
RxNorm normalized name: beclomethasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beclometasone
Trial: 11586012
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg elemental zinc
Trial: 11586012
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg minocycline
Trial: 2720725
Drug: Stuart Prenatal
RxNorm normalized name: Stuart Prenatal + DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stuart Prenatal tablet
Trial: 23211514
Drug: Mixed-nutrient drink
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-nutrient drink (500 ml, 532 kcal)
Trial: 18086493
Drug: Fluticasone inhalation
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone inhalation (single dose)
Trial: 18086493
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg racemic albuterol after fluticasone pretreatment
Trial: 18086493
Drug: Albuterol formulations
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol formulations after placebo or fluticasone pretreatment
Trial: 16130018
Drug: Functional electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional electrical therapy (N=12)
Trial: 8674162
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (250, 500, 750, 1000, 1200 mg/m2) infused over 2 hours on days 1 and 2, with G-CSF 5 micrograms/kg per day starting on day 3 until WBC was > or = 10,000/microliters
Trial: 1898644
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus medical treatment
Trial: 6344715
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide plus low-dose prednisone
Trial: 6344715
Drug: Oral azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azathioprine plus low-dose prednisone
Trial: 30794084
Drug: TRT+RT (Testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRT+RT (Testosterone Replacement Therapy + Resistance Training)
Trial: 26896232
Drug: Early introduction
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early introduction group (EIG) with sequential introduction of 6 allergenic foods: cow's milk, peanut, hard-boiled hen's egg, sesame, whitefish (cod), and wheat; continued breastfeeding.
Trial: 25142305
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000mg daily)
Trial: 22581994
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m² intravenously) as add-on therapy
Trial: 22581994
Drug: Prednisone and
RxNorm normalized name: chloroprednisone and antiinfectives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone and calcineurin inhibitors (standard treatment)
Trial: 17445857
Drug: Two concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two concurrent moving stimuli
Trial: 16087005
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sandblasting and laser etching at 4.0 J/cm2 (Group V)
Trial: 7747375
Drug: Isotretinoin 1
RxNorm normalized name: isotretinoin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 1 mg/kg orally daily until remission (max 3 months)
Trial: 7747375
Drug: Interferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2a 3 x 10(5) IU subcutaneously three times weekly plus isotretinoin 1 mg/kg orally daily until remission (max 8 weeks)
Trial: 29910795
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cell/tumor antigen vaccine (ADCTA) in conjunction with concomitant chemoradiotherapy (CCRT) with temozolomide
Trial: 29910795
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment without immunotherapy
Trial: 26750130
Drug: PCV (procarbazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV (procarbazine, CCNU, vincristine) chemotherapy following radiotherapy (RT)
Trial: 18386581
Drug: TCM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM therapy combined with radiotherapy
Trial: 12602446
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg fexofenadine (F)
Trial: 12602446
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diphenhydramine (D)
Trial: 10982197
Drug: Slow-release melatonin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release melatonin, 2 mg/day for 4 weeks
Trial: 8828240
Drug: Cognitive-behavioural intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural intervention (6 sessions) in addition to usual methadone maintenance treatment
Trial: 8828240
Drug: Usual methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual methadone maintenance treatment only
Trial: 1349509
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of loratadine once daily
Trial: 1349509
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of hydroxyzine thrice daily
Trial: 1349509
Drug: Placebo thrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo thrice daily
Trial: 3882583
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate cream
Trial: 3882583
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate sustained-release tablets
Trial: 24642828
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol (5 mL/kg)
Trial: 24642828
Drug: 3% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% hypertonic saline (5 mL/kg)
Trial: 22613428
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.3 mg) plus patient-controlled analgesia (PCA)
Trial: 16394436
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole 100 mg, two capsules twice daily for seven days a month for four months.
Trial: 16394436
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine 250 mg, one tablet twice daily for seven days every month for four months.
Trial: 4009554
Drug: Prenatal supplement
RxNorm normalized name: CVS DHA Prenatal Supplement 200mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal supplement with reduced amounts of calcium and magnesium
Trial: 4009554
Drug: Two other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two other prenatal supplements
Trial: 30156758
Drug: ABBV-257 30
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-257 30 mg/kg subcutaneously every other week for 8 weeks
Trial: 30156758
Drug: ABBV-257 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-257 (various doses: 0.3, 1.0, and 3.0 mg/kg intravenously; 0.3 and 3.0 mg/kg subcutaneously)
Trial: 30156758
Drug: ABBV-257 (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-257 (single-dose study)
Trial: 30156758
Drug: ABBV-257 (multiple-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-257 (multiple-dose study)
Trial: 30351407
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system inhibitors (RASi)
Trial: 30351407
Drug: Non-renin-angiotensin system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-renin-angiotensin system inhibitors (non-RASi)
Trial: 27456597
Drug: Microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose nasal spray
Trial: 17388220
Drug: Fexofenadine hydrochloride
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride 180 mg once daily
Trial: 10795758
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg intravenous) during normoglycemia (5-8.9 mmol/liter glucose)
Trial: 10795758
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg intravenous) during hyperglycemia (16-19 mmol/liter glucose)
Trial: 1485474
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg dipyridamole per day
Trial: 18812486
Drug: Oral DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral DHEA 50 mg/d for 12 months
Trial: 16480006
Drug: Biological valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological valve (Medtronic Mosaic or Medtronic Freestyle)
Trial: 8393272
Drug: Chemohormonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemohormonal therapy (group A) including 60 mg/m2 of cisplatin (CDDP), 13 mg/m2 of Adriamycin (ADM), 150 mg of 5‐fluorouracil (5‐FU), Tamoxifen (TAM) 25 mg/m2 daily, and medroxyprogesterone acetate (MPA) 400 mg/m2 daily, administered orally and alternated every 4 weeks
Trial: 8393272
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group B) receiving the same anticancer drugs without hormonal agents
Trial: 29161531
Drug: Inhaled levodopa
RxNorm normalized name: levodopa Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled levodopa (CVT-301) 25 mg
Trial: 29161531
Drug: Inhaled levodopa
RxNorm normalized name: levodopa Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled levodopa (CVT-301) 50 mg
Trial: 29161531
Drug: Inhaled levodopa
RxNorm normalized name: levodopa Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled levodopa (CVT-301) 35 mg (weeks 1-2)
Trial: 29161531
Drug: Inhaled levodopa
RxNorm normalized name: levodopa Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled levodopa (CVT-301) 50 mg (weeks 3-4)
Trial: 28009467
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) for 10 weeks, including six online therapy lessons with content summaries and homework assignments
Trial: 25627338
Drug: Golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 50 mg or 100 mg (based on escape status)
Trial: 22981787
Drug: Cat-PAD (6-nmol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cat-PAD (6-nmol dose, 4 administrations, 4 weeks apart)
Trial: 22981787
Drug: Cat-PAD (3-nmol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cat-PAD (3-nmol dose, 8 administrations, 2 weeks apart)
Trial: 17938887
Drug: Heparinized solution
RxNorm normalized name: heparin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized solution (1 IU/ml)
Trial: 17938887
Drug: Heparinized solution
RxNorm normalized name: heparin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized solution
Trial: 17053959
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion with saline and intravenous infusion of octreotide
Trial: 7538658
Drug: Lenograstim (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim (twice daily on alternate days)
Trial: 7538658
Drug: Lenograstim therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim therapy
Trial: 3262980
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of 1 ml of lignocaine (10 mg) to 19 ml of propofol
Trial: 3262980
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline added to 19 ml of propofol
Trial: 21424272
Drug: Treatment supporter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment supporter intervention (TS arm)
Trial: 9682999
Drug: Amisulpride (ASP)
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amisulpride (ASP) 1000 mg/day (mean daily dose: 956 mg)
Trial: 9682999
Drug: Flupentixol (FPX)
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol (FPX) 25 mg/day (mean daily dose: 22.6 mg)
Trial: 8562296
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (captopril or enalapril)
Trial: 8562296
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-ACE inhibitors)
Trial: 120757
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (maximum tolerated doses)
Trial: 28385352
Drug: MLE4901 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLE4901 (40 mg, orally, twice daily)
Trial: 28385352
Drug: Placebo (orally,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (orally, twice daily)
Trial: 24083696
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Ringer's solution)
Trial: 17916806
Drug: tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium 18 microg once daily
Trial: 7163513
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no oxytocin infusion)
Trial: 27114421
Drug: Sequential Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Therapy (ST) for 10 days
Trial: 27114421
Drug: Triple Therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple Therapy (TT) for 7 days
Trial: 25270152
Drug: Rituximab as
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab as induction therapy after renal transplantation
Trial: 20200306
Drug: Age and
RxNorm normalized name: wound drainage and fistula management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age and insulin modality (pump vs multiple daily injections)
Trial: 16808313
Drug: Pentaerythritol compositum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaerythritol compositum (20 mg of pentaerythritol tetranitrate and 0.5 mg of nitroglycerine)
Trial: 16808313
Drug: Nitroglycerine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine (0.5 mg)
Trial: 12011664
Drug: ASA 75
RxNorm normalized name: ASA 75 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 75 mg daily
Trial: 2407227
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion with doxorubicin hydrochloride (Adriamycin) 30 mg every 24 hours for 3 days, followed by irradiation (30 or 35 Gy in 10 fractions or 46 Gy in 23 to 25 fractions)
Trial: 27966318
Drug: Levofloxacin administration
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin administration after EMR (Group B)
Trial: 27966318
Drug: Ceftazidime administration
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime administration after EMR (Group C)
Trial: 27966318
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics treatment after EMR (Group A)
Trial: 25730927
Drug: Low-frequency magnetic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency magnetic therapy
Trial: 15721091
Drug: Bucindolol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bucindolol therapy
Trial: 10535346
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg mifepristone orally followed by gemeprost 1 mg vaginally 24 hours later
Trial: 10535346
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg mifepristone orally followed by gemeprost 1 mg vaginally 48 hours later
Trial: 1654983
Drug: As required
RxNorm normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As required (AR) chemotherapy
Trial: 1654983
Drug: Planned chemotherapy
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Planned chemotherapy
Trial: 1654983
Drug: As required
RxNorm normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As required (AR) chemotherapy with treatment-free interval (TFI) greater than 8 weeks
Trial: 1654983
Drug: As required
RxNorm normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As required (AR) chemotherapy with treatment-free interval (TFI) less than 4 weeks
Trial: 26598747
Drug: Alectinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib 600 mg orally twice daily
Trial: 24339179
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, followed by either CZP 200 mg every 2 weeks or CZP 400 mg every 4 weeks
Trial: 24339179
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 200 mg every 2 weeks or CZP 400 mg every 4 weeks
Trial: 22903484
Drug: No bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bowel preparation and allowed to eat and drink before examination (group 2)
Trial: 15260469
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow at 20 L/min
Trial: 15260469
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow at 60 L/min
Trial: 9688295
Drug: Cisplatin (DDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (DDP) in combination with ifosfamide (IFO) and vinorelbine (VNB)
Trial: 9688295
Drug: Ifosfamide (IFO)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide (IFO) and vinorelbine (VNB) plus G-CSF
Trial: 8075441
Drug: 0.3% podophyllotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% podophyllotoxin cream
Trial: 782964
Drug: H3N2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3N2 vaccine
Trial: 782964
Drug: HEqN2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEqN2 vaccine
Trial: 782964
Drug: Placebo vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaccine (vaccine diluent)
Trial: 31612398
Drug: USG II/IHN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USG II/IHN plus GFN block (Group G)
Trial: 19228800
Drug: Home telemonitoring
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home telemonitoring (HT) - three strategies: (i) monthly telephone contact; (ii) monthly telephone contact plus weekly transmission of vital signs; (iii) strategy 2 plus monthly 24 h recording of cardiorespiratory activity